medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2014, Número 3

<< Anterior Siguiente >>

Residente 2014; 9 (3)


Síndrome metabólico en artritis reumatoide

Dávalos-de la Cruz AP, Flores-Chávez A, Hernández-Cuervo P, Romero-Moreno JR, Félix-Hernández F, Aguilar-Ríos EG, Rodríguez-Hernández TM, González-López L

Idioma: Español
Referencias bibliográficas: 61
Paginas: 106-115
Archivo PDF: 231.45 Kb.


RESUMEN

El síndrome metabólico (SM) es un conjunto de factores de riesgo para enfermedades cardiovasculares; sus principales componentes son hipertrigliceridemia, hipertensión, niveles disminuidos de colesterol HDL, obesidad central y resistencia a la insulina. La prevalencia del SM en población general en México es del 41.6%. En pacientes con artritis reumatoide (AR), la prevalencia de SM varía del 16.2 al 40.9%. En los últimos 20 años, la expectativa de vida en pacientes con AR se ha reducido de 3 a 10 años en comparación con la población sana. Su relación con la prevalencia de SM aún no ha sido aclarada totalmente. Se ha sugerido una asociación entre la inflamación característica de la AR y el proceso de desarrollo del SM, al igual que una alta incidencia de SM en pacientes con la patología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365 (9468): 1415-1428.

  2. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, Morelos. Instituto Nacional de Salud Pública (MX); 2012.

  3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine. 1998; 15 (7): 539-553.

  4. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine. 1999; 16 (5): 442-443.

  5. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Disponible en: http://www.idf.org/metabolic-syndrome.

  6. Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine Practice. 2003; 9 (3): 237-252.

  7. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association. 2001; 285 (19): 2486-2497.

  8. Jaspinder Kaur. A comprehensive review on metabolic syndrome. Cardiology Research and Practice. 2004; 1-2.

  9. Ferraz AI, González JC, López MR, Riancho ZL, González GMA. Metabolic syndrome in rheumatoid arthritis: mediators of inflammation. Hindawi. 2013; 13: 1.

  10. Ferraz AI, González JC, López MR, Riancho ZL, González GMA. Metabolic syndrome in rheumatoid arthritis: mediators of inflammation. Hindawi. 2013; 13: 3.

  11. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA). A study of 5 regions based on the COPCORD methodology. J Rheumatol. 2011; 86: 3-8.

  12. Morales RJ, Cázares MJM, Gámez NJI, Triano PM, Villa MAI, López OMA, Rodríguez ABE, González LL. La atención médica en reumatología en un hospital de segundo nivel de atención. Reumatol Clin. 2005; 1 (2): 87-94.

  13. Cojocaru M, Cojocaru I, Silosi I, Vrabie C. Metabolic syndrome in rheumatoid arthritis. A Journal of Clinical Medicine. 2012; 7: 21.

  14. Chung CP, Oeser A, Solus JF et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary aterosclerosis. Atherosclerosis. 2008; 196 (2): 756-763.

  15. Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2010; 12 (6): R218.

  16. Da Cunha VR, Brenol CV, Brenol JCT et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scandinavian Journal of Rheumatology. 2012; 41 (3): 186-191.

  17. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. Journal of Clinical Rheumatology. 2008; 14 (2): 74-77.

  18. Rostom S, Mengat M, Lahlo R, Hari A, Bahiri R, Hajjaj-Hassouni N. Metabolic syndrome in rheumatoid arthritis: case control study. BMC Musculoskeletal Disorders. 2013; 14:147.

  19. Karakoc M, Batmaz I, Sariyildiz MA, Tahtasiz M, Cevik R, Tekbas E et al. The relationship of metabolic syndrome with disease activity and the functional status in patients with rheumatoid arthritis. J Clin Med Res. 2012; 4 (4): 279-285.

  20. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Obesity in rheumatoid arthritis. Rheumatology. 2011; 50 (3): 450-462.

  21. Giles JT, Allison M, Blumenthal RS et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis and Rheumatism. 2010; 62 (11): 3173-3182.

  22. Elkan AC1, Håkansson N, Frostegård J, Cederholm T, Hafström I. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Research and Therapy. 2009; 11 (2): R37.

  23. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber L. Inflammatory cytokines in pulmonary hypertension. Respiratoty Research. 2014; 15: 47-43.

  24. Rodriguez H, Simental L, Rodriguez G, Reyes M. Obesity and inflammation: epidemiology, risk factors and markers of inflammation. International Journal of Endocrinology. 2013; 2013 3.

  25. Ferraz AI, Díaz GF, González JC, González GMA. Insulin resistance and rheumatoid arthritis. Reumatologia Clinica. 2011; 7 (2): 124-129.

  26. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diabetes Vasc Dis Res. 2007; 4: 130-135.

  27. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol. 2007; 34: 681-688.

  28. Pamuk ON, Unlü E, Cakir N. Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. J Rheumatol. 2006; 33: 2447-2452.

  29. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol. 2002; 29: 462-466.

  30. Rodriguez LA, Tolosa LB, Ruigmez A, Johansson S, Wallander MA. Rheumatoid arthritis in UK primary care incidence and prior morbidity. Scandinavian Journal of Rheumatology. 2009; 38 (3): 173-177.

  31. La Montagna G, Cacciapuoti F, Buono R et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diabetes and Vascular Disease Research. 2007; 4 (2): 130-135.

  32. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A. Independent role of conventional cardiovascular risk factors as predictors of c-reactive protein concentrations in rheumatoid arthritis. Journal of Rheumatology. 2007; 34 (4): 681-688.

  33. Pamuk ON, Unlu E, Cakir N. Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. Journal of Rheumatology. 2006; 33 (12): 2447-2452.

  34. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. Journal of Rheumatology. 2002; 29 (3): 462-466.

  35. Goshayeshi L, Saber HR, Sahebari M, Rezaieyazdi Z, Rafatpanah H et al. Association between metabolic syndrome, BMI, and serum vitamin D concentrations in rheumatoid arthritis. Clin Rheumatol. 2012; 31: 1-7.

  36. Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante. A high incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44: 2737-2745.

  37. Maldonado Auccahuallpa M, Cefferino Hidalgo C, Hidalgo García A, Arbañil Huamán H. Frecuencia del síndrome metabólico en pacientes con artritis reumatoide que acuden al Servicio de Reumatología de un hospital nacional. Revista Peruana de Reumatología. 2008; 14 (1): 17.

  38. Zhang J, Fu L, Shi J, Chen X, Li Y, Bing Ma, Zhang Y. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. Plos One. 2013; 8: 1-3.

  39. Crowson CS, Myasoedova E, Davis JM, Matteson EL, Roger VL, Therneau TM et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol. 2011; 38 (1): 29-35.

  40. Cojocaru M, Cojocaru I, Silosi I, Vrabie C. Metabolic syndrome in rheumatoid arthritis. A Journal of Clinical Medicine. 2012; 7 (2): 1-3.

  41. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nature Clinical Practice Rheumatology. 2007; 12: 716-724.

  42. Pasquali R, Vicennati V. Steroids and the metabolic syndrome. J Steroid Biochem Mol Biol. 2008; 109: 258-265.

  43. Otero M, Lago R, Gomez R et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65 (9): 1198-1201.

  44. Conde J, Scotece M, Gomez R et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity,” BioFactors. 2011; 37 (6): 413-420.

  45. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesionmolecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100 (25): 2473-2476.

  46. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circulation Journal. 2004; 68 (11): 975-981.

  47. Fonseca AMH, Takada J, Alonso VMI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Río J). 2007; 83: 192-203.

  48. Fruhbeck G. A heliocentric view of leptin. Proc Nutr Soc. 2001; 60: 301-318.

  49. Kadowaki T, Yamauchi T, Kubota N, hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116: 1784-1792.

  50. Toms TE, Panoulas VF, John H, Douglas KMJ, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60--More than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther. 2009; 11: 110.

  51. Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008; 14 (2): 74-77.

  52. Nicola PJ, Maradit-Kremers H, Roger VL et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005; 52: 412-420.

  53. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M: Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol. 2004; 31: 867-874.

  54. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008; 371: 1927-1935.

  55. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, C, Institute/American Heart Association Conference on Scientific Issues Related to Definition of Metabolic Syndrome: Report of the National Heart. Lung and Blood. 2012.

  56. Whelton PK, He J, Appel LJ et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. Journal of the American Medical Association. 2002; 288 (15): 1882-1888.

  57. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. Journal of the American Medical Association. 2003; 289 (19): 2560-2572.

  58. Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M. Metabolic syndrome: treatment of hypertensive patients. The American Journal of Therapeutics. 2007; 14 (4): 386-402.

  59. Ball SG, White WB. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers -a gap in evidence-based medicine. The American Journal of Cardiology. 2003; 91 (10): 15G-21G.

  60. Barnett SC, Bain P, Bouter et al. Angiotensin receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. The New England Journal of Medicine. 2004; 351 (19): 1952-1961.

  61. Pasternak RC. The ALLHAT lipid lowering trial-less is less. Journal of the American Medical Association. 2002; 288 (23): 3042-3044.




2020     |     www.medigraphic.com